Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.

Literature DB >> 2940966

In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.

Abstract

Seven quinolone antibiotics were tested against 115 isolates of methicillin-resistant Staphylococcus aureus. The MICs for 90% of the strains tested were 0.5 microgram/ml for A-56619, A-56620, ciprofloxacin, and ofloxacin; 2.0 micrograms/ml for amifloxacin and enoxacin; and 4.0 micrograms/ml for norfloxacin. Killing kinetic studies showed a similar killing rate for all seven antibiotics.

Entities: Chemical Species

Mesh：

Substances：

Year: 1986 PMID： 2940966 PMCID： PMC176400 DOI： 10.1128/AAC.29.2.325

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

14 in total

1. The emergence of methicillin-resistant Staphylococcus aureus.

Authors: R P Wenzel
Journal: Ann Intern Med Date: 1982-09 Impact factor: 25.391

2. Antimicrobial spectrum of Win 49375.

Authors: N V Jacobus; F P Tally; M Barza
Journal: Antimicrob Agents Chemother Date: 1984-07 Impact factor: 5.191

3. Treatment of infections due to methicillin-resistant Staphylococcus aureus.

Authors: C Watanakunakorn
Journal: Ann Intern Med Date: 1982-09 Impact factor: 25.391

4. Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks.

Authors: L D Saravolatz; D J Pohlod; L M Arking
Journal: Ann Intern Med Date: 1982-09 Impact factor: 25.391

5. Multiply antibiotic-resistant Staphylococcus aureus: introduction, transmission, and evolution of nosocomial infection.

Authors: R M Locksley; M L Cohen; T C Quinn; L S Tompkins; M B Coyle; J M Kirihara; G W Counts
Journal: Ann Intern Med Date: 1982-09 Impact factor: 25.391

6. In vitro and in vivo activity of DL-8280, a new oxazine derivative.

Authors: K Sato; Y Matsuura; M Inoue; T Une; Y Osada; H Ogawa; S Mitsuhashi
Journal: Antimicrob Agents Chemother Date: 1982-10 Impact factor: 5.191

7. Open, prospective study of the clinical efficacy of ciprofloxacin.

Authors: C A Ramirez; J L Bran; C R Mejia; J F Garcia
Journal: Antimicrob Agents Chemother Date: 1985-07 Impact factor: 5.191

8. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.

Authors: N X Chin; H C Neu
Journal: Antimicrob Agents Chemother Date: 1983-11 Impact factor: 5.191

9. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors: A Bauernfeind; C Petermüller
Journal: Eur J Clin Microbiol Date: 1983-04 Impact factor: 3.267

10. Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections.

Authors: E J Goldstein; M L Alpert; B P Ginsberg
Journal: Antimicrob Agents Chemother Date: 1985-03 Impact factor: 5.191

23 in total

In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin, and ofloxacin against methicillin-resistant Staphylococcus aureus.

1. The emergence of methicillin-resistant Staphylococcus aureus.

2. Antimicrobial spectrum of Win 49375.

3. Treatment of infections due to methicillin-resistant Staphylococcus aureus.

4. Community-acquired methicillin-resistant Staphylococcus aureus infections: a new source for nosocomial outbreaks.

5. Multiply antibiotic-resistant Staphylococcus aureus: introduction, transmission, and evolution of nosocomial infection.

6. In vitro and in vivo activity of DL-8280, a new oxazine derivative.

7. Open, prospective study of the clinical efficacy of ciprofloxacin.

8. In vitro activity of enoxacin, a quinolone carboxylic acid, compared with those of norfloxacin, new beta-lactams, aminoglycosides, and trimethoprim.

9. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

10. Norfloxacin versus trimethoprim-sulfamethoxazole in the therapy of uncomplicated, community-acquired urinary tract infections.

Review 1. Clinical importance and epidemiology of quinolone resistance.

2. Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations.

Review 3. Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Review 4. Enoxacin: a reappraisal of its clinical efficacy in the treatment of genitourinary tract infections.

5. In vitro activity of AT-4140 against clinical bacterial isolates.

Review 6. Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Review 7. Clinical pharmacokinetics of ciprofloxacin.

8. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

9. In vitro activities of amifloxacin and two of its metabolites.

10. Comparative evaluation of identification systems for testing methicillin-resistant strains of Staphylococcus aureus.